Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

"MAPping" the course of chemoprevention in breast cancer.

Davidson NE, Kensler TW.

N Engl J Med. 2011 Jun 23;364(25):2463-4. doi: 10.1056/NEJMe1106052. Epub 2011 Jun 4. No abstract available.

PMID:
21639807
2.

Exemestane for breast-cancer prevention.

Hanaoka M, Takano T, Kawabata H.

N Engl J Med. 2011 Sep 15;365(11):1056-7; author reply 1057-8. doi: 10.1056/NEJMc1108287#SA2. No abstract available.

PMID:
21916645
3.

Exemestane for breast-cancer prevention.

Zeng YC, Xiao YP, Xue M.

N Engl J Med. 2011 Sep 15;365(11):1057; author reply 1057-8. doi: 10.1056/NEJMc1108287#SA3. No abstract available.

PMID:
21916644
4.

Aromatase inhibitor adverse effects: are we sweeping them under the rug?

Niravath P, Rimawi MF, Osborne CK.

J Clin Oncol. 2014 Nov 20;32(33):3779. doi: 10.1200/JCO.2014.56.9640. Epub 2014 Aug 25. No abstract available.

PMID:
25154832
5.

Exemestane for breast-cancer prevention.

Tartarone A.

N Engl J Med. 2011 Sep 15;365(11):1056; author reply 1057-8. doi: 10.1056/NEJMc1108287#SA1. No abstract available.

PMID:
21916646
6.

National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.

Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, Ingle JN, Alés-Martinez JE.

Clin Breast Cancer. 2007 Dec;7(11):895-900. doi: 10.3816/CBC.2007.n.057. No abstract available.

PMID:
18269782
7.

[Chemoprevention of breast cancer: exemestane ready to be tested in study setting].

Verkooijen HM, van Diest PJ, Peeters PH.

Ned Tijdschr Geneeskd. 2012;156(1):A4217. Dutch.

PMID:
22217312
8.

Reply to P. Niravath et Al.

Maunsell E, Chlebowski RT, Ingle JN, Richardson H, Goss PE.

J Clin Oncol. 2014 Nov 20;32(33):3780-1. doi: 10.1200/JCO.2014.57.9235. Epub 2014 Aug 25. No abstract available.

PMID:
25154825
9.

Chemoprevention in breast cancer.

Vogel V.

Clin Adv Hematol Oncol. 2005 Jul;3(7):531-3. Review. No abstract available.

PMID:
16167032
10.

Breast cancer chemoprevention.

Gabriel EM, Jatoi I.

Expert Rev Anticancer Ther. 2012 Feb;12(2):223-8. doi: 10.1586/era.11.206. Review.

PMID:
22316370
11.

Exemestane for breast cancer prevention: a feasible strategy?

Lønning PE.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):918s-24s. Review.

12.

Breast cancer risk reduction therapy: the low-hanging fruit.

Bevers TB.

J Natl Compr Canc Netw. 2015 Apr;13(4):376-8. No abstract available.

PMID:
25870373
13.

Chemoprevention of breast cancer.

Cuzick J.

Breast Cancer. 2008;15(1):10-6. doi: 10.1007/s12282-007-0006-z.

PMID:
18224388
14.

Aromatase inhibitors in breast cancer prevention.

Olin JL, St Pierre M.

Ann Pharmacother. 2014 Dec;48(12):1605-10. doi: 10.1177/1060028014548416. Epub 2014 Aug 26. Review.

PMID:
25159003
15.

Exemestane for primary prevention of breast cancer in postmenopausal women.

Zhang Y, Simondsen K, Kolesar JM.

Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585.

PMID:
22855103
16.

When to start an aromatase inhibitor: now or later?

Doughty JC.

J Surg Oncol. 2011 Jun 1;103(7):730-8. doi: 10.1002/jso.21801. Epub 2011 Feb 24. Review.

PMID:
21360530
17.

Switching to aromatase inhibitors in early breast cancer.

Boccardo F, Rubagotti A.

Lancet. 2007 Feb 17;369(9561):533-5. No abstract available.

PMID:
17307082
18.

Aromatase inhibitors and breast cancer: time for a change?

Fentiman IS.

Int J Clin Pract. 2004 Dec;58(12):1152-8. Review.

PMID:
15646413
19.

Adjuvant ovarian suppression in premenopausal breast cancer.

Montemurro F, Perrone F, Geuna E.

N Engl J Med. 2015 Apr 23;372(17):1672-3. doi: 10.1056/NEJMc1502618#SA1. No abstract available.

PMID:
25901438
20.

Adjuvant ovarian suppression in premenopausal breast cancer.

Francis PA, Regan MM, Fleming GF.

N Engl J Med. 2015 Apr 23;372(17):1673. doi: 10.1056/NEJMc1502618. No abstract available.

Supplemental Content

Support Center